Can Antidepressants Cause Bladder Problems?

Antidepressants can and do cause bladder problems, ranging from difficulty emptying the bladder to sudden urgency and leakage. A systematic review and meta-analysis found that tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors carry higher odds of voiding dysfunction than selective serotonin reuptake inhibitors, though SSRIs are not risk-free either.¹ The tricky part is that different antidepressants can produce opposite bladder effects depending on the drug’s pharmacology and the person taking it, which makes this side effect both underrecognized and genuinely confusing for patients.

How Antidepressants Interfere With Normal Bladder Function

Your bladder relies on a coordinated dance between nerves, muscles, and chemical signals. When the bladder fills, your brain suppresses the urge to contract until you’re ready. When you decide to urinate, the brain releases that brake, the bladder muscle squeezes, and the urethral sphincter relaxes. Antidepressants can disrupt this process at several points because the same chemical messengers they target in the brain, especially serotonin and norepinephrine, are also deeply involved in bladder control.

Serotonin receptors play a direct role in how the brain regulates when the bladder contracts. Animal research has identified several serotonin receptor subtypes that either encourage or suppress bladder contractions, with the net effect of boosting serotonin levels in the spinal cord usually being suppression of the voiding reflex.² That suppression can manifest as difficulty starting urination or an inability to fully empty the bladder. Research in rats has shown that serotonin receptors in the prefrontal cortex also fine-tune how often the bladder contracts, with different receptor subtypes pushing the timing in opposite directions.³

Norepinephrine adds another layer. This chemical tightens the urethral sphincter, and drugs that increase norepinephrine levels at the urethra can raise the pressure needed to release urine. Research on selective norepinephrine reuptake inhibitors has demonstrated dose-dependent increases in urethral pressure in animal models.⁴ That same mechanism explains why norepinephrine reuptake inhibitors can both treat stress incontinence (by strengthening the sphincter) and cause urinary retention (by making the sphincter too tight to open easily).⁵

Then there are anticholinergic effects. Many antidepressants, especially older tricyclics, block acetylcholine receptors. Since acetylcholine is the signal that tells the bladder muscle to squeeze, blocking it can reduce bladder contractions and lead to retention. Tricyclic antidepressants like imipramine combine anticholinergic effects with additional properties that relax the bladder dome, creating a strong dual suppression of bladder activity.⁶

Which Antidepressant Classes Carry the Most Risk

Not all antidepressants affect the bladder equally. The systematic review comparing drug classes found that tricyclics and SNRIs had higher odds of causing voiding problems than SSRIs.¹ This makes pharmacological sense: tricyclics hit multiple receptor systems at once (anticholinergic, serotonergic, noradrenergic), and SNRIs boost both serotonin and norepinephrine, giving them two separate routes to tighten the urethral sphincter and suppress bladder contractions.

Among individual drugs, the picture varies considerably. A systematic review focused on urinary retention found that imipramine, the prototypical tricyclic, caused retention in about 18% of patients in studies that carefully defined the condition, though when all tricyclics were pooled together the rate dropped to around 0.1%, likely reflecting less rigorous definitions of retention in some studies.⁷ For duloxetine, an SNRI, placebo-controlled trials showed that obstructive voiding symptoms occurred in about 1% of duloxetine-treated patients compared to roughly 0.4% on placebo, and no cases of acute retention requiring catheterization were reported.⁸

SSRIs have traditionally been considered lower risk, but they are far from innocent. A large pharmacoepidemiological study of over 13,000 first-time SSRI users found the risk of urinary incontinence was roughly 60% higher during SSRI use compared to baseline. In older patients, the absolute numbers were more striking: roughly 60 extra cases of incontinence per 1,000 patients treated per year. Among individual SSRIs, sertraline users had the highest risk in that study.⁹ A pharmacovigilance analysis of the FDA’s adverse event database also flagged fluoxetine as carrying a confirmed signal for urinary retention, a finding that was validated in a separate Canadian database.¹⁰

Even atypical antidepressants that don’t fit neatly into the major classes can cause bladder issues. Mirtazapine, which works partly through antihistamine and noradrenergic effects, has been reported to cause urinary retention, particularly in older men with enlarged prostates.¹¹ Bupropion, which primarily affects dopamine and norepinephrine and is often considered to have a cleaner side-effect profile, has been linked to urinary incontinence during sleep in at least one documented case.¹²

Overactive Bladder Versus Urinary Retention

One of the most confusing aspects of antidepressant-related bladder problems is that they can go in either direction. Some people develop urinary retention, where the bladder doesn’t empty properly, while others develop overactive bladder, with sudden urgency, frequent trips to the bathroom, and sometimes leakage. Both can happen with the same class of drug.

A prospective study of male antidepressant users found that about half met criteria for overactive bladder, compared to roughly 14% of men not taking antidepressants. The risk varied substantially by drug: venlafaxine users had the highest rate at about 68%, while sertraline users had the lowest at about 28%.¹³ A similar study in women found overactive bladder in about 64% of antidepressant users versus 33% of controls. In that study, fluoxetine users had the highest rate, but again sertraline users had among the lowest.¹⁴

How can the same drugs cause both an overly active bladder and an underactive one? The answer lies in how these medications interact with different parts of the urinary tract. Serotonin and norepinephrine reuptake inhibition tends to suppress the bladder’s ability to contract and to tighten the urethral sphincter, which can lead to retention. But these drugs also alter signaling in the brain centers that coordinate urination, and for some people those central effects may paradoxically increase bladder irritability. Additionally, if the bladder can’t empty fully because of partial retention, the residual urine can itself trigger urgency and frequency, creating overactive bladder symptoms on top of an underlying emptying problem.

Who Is Most Vulnerable

Older adults face a disproportionate risk. Aging naturally changes bladder function, and conditions like an enlarged prostate in men or weakened pelvic floor muscles in women reduce the margin for error. When you layer an antidepressant’s bladder effects on top of these age-related changes, problems can emerge that might not appear in a younger person taking the same drug.

The anticholinergic burden concept is especially relevant here. Many older adults take multiple medications that each have mild anticholinergic properties. Individually, each drug might not cause a noticeable problem, but together they can add up to produce significant side effects including dry mouth, constipation, and urinary retention, along with potential cognitive effects.¹⁵ An antidepressant with even modest anticholinergic activity might push someone over the threshold when combined with an antihistamine, a bladder medication, or an antipsychotic.

Older men with benign prostatic hyperplasia are at particular risk for acute urinary retention, which is a medical emergency. A case series documented three elderly men who developed acute retention after starting escitalopram, an SSRI generally considered to have minimal anticholinergic effects. Two recovered after stopping the drug, but one required emergency surgery.¹⁶ The fact that even a relatively “clean” SSRI could trigger such a severe outcome suggests that any man with known or suspected prostate enlargement should have his urinary function monitored when starting an antidepressant.

Adults with overactive bladder also tend to have more chronic conditions and take more medications overall, which raises the potential for drug interactions.¹⁷ If your bladder is already somewhat compromised, adding an antidepressant to the mix is more likely to push things into symptomatic territory.

The Duloxetine Paradox

Here is where things get genuinely counterintuitive: one of the most commonly prescribed SNRIs, duloxetine, is actually used in some countries to treat stress urinary incontinence. The drug’s ability to boost serotonin and norepinephrine levels strengthens the urethral sphincter, which helps prevent leakage during coughing, sneezing, or physical activity. Clinical trials showed that women taking duloxetine for stress incontinence had fewer leakage episodes and reported meaningful quality-of-life improvements.¹⁸

This dual personality highlights something important about how antidepressants affect the bladder: the same pharmacological action can be therapeutic or harmful depending on the baseline state of the patient’s urinary tract. A person with a weak sphincter leaking urine may benefit from the sphincter-tightening effect. A person with normal sphincter function or an enlarged prostate may find that same tightening makes urination difficult. Duloxetine’s use in incontinence isn’t approved in every country, partly because the benefit has to be weighed against the risk of pushing some patients toward retention. In clinical trials for depression, duloxetine caused obstructive voiding symptoms in about 1% of patients, a rate low enough to be tolerable in depression treatment but worth knowing about.⁸

Children and Adolescents

Bladder side effects from antidepressants are not limited to adults. An analysis of the FDA’s adverse event reporting system identified antidepressants, including sertraline, fluoxetine, and citalopram, as showing stronger signals for urinary incontinence and bedwetting in pediatric patients compared to adults.¹⁹ Nervous system drugs accounted for the majority of medications flagged for drug-induced urinary incontinence in children.

The relationship between antidepressants and children’s bladder function has an interesting flip side. Fluoxetine has been studied as a potential treatment for primary bedwetting in children who haven’t responded to standard treatments. A randomized, placebo-controlled trial found that after four weeks, roughly two-thirds of children on fluoxetine achieved at least a 50% reduction in wet nights, compared to about 17% on placebo. The effect weakened over the 12-week study period, suggesting it may not be a durable solution, but it illustrates the same paradox seen with duloxetine in adults: these drugs can both cause and treat bladder problems depending on the circumstances.²⁰

What to Do If You Suspect a Problem

If you’ve started an antidepressant and notice changes in how often you urinate, difficulty starting or maintaining a stream, a sudden feeling of urgency, or new episodes of leakage, it is worth raising with your prescriber. These symptoms often emerge within the first weeks of treatment or after a dose increase, but they can also develop gradually over months.

The first-line approach for drug-induced urinary retention is typically catheterization if the retention is acute, combined with stopping or reducing the dose of the drug responsible.²¹ In less urgent situations, switching to an antidepressant with a different pharmacological profile may resolve the problem while still treating the depression. For example, someone experiencing retention on a tricyclic might do better on an SSRI with lower anticholinergic activity, while someone developing overactive bladder symptoms on venlafaxine might tolerate sertraline, which showed lower rates of overactive bladder in multiple studies.¹³

The challenge, of course, is that switching antidepressants is not trivial. Finding an effective medication for depression often involves trial and error, and nobody wants to abandon a drug that is working for their mood because of a bladder issue. In some cases, managing the bladder side effect directly, through behavioral strategies like timed voiding or pelvic floor exercises, may be preferable to changing the antidepressant. This is a conversation to have with your doctor rather than a decision to make on your own, since abruptly stopping an antidepressant carries its own risks.

Why This Side Effect Gets Overlooked

Bladder problems on antidepressants are probably more common than reported. One reason is embarrassment: people may not mention urinary symptoms to a psychiatrist, and they may not connect the symptom to the medication when they do see a urologist. Another is that depression itself can alter bladder function through stress-related pathways, making it harder to tell whether the drug or the underlying condition is responsible.

The pharmacovigilance data reinforces this underrecognition problem. Fluoxetine, one of the most widely prescribed SSRIs in the world, was flagged as having an “unexpected” signal for urinary retention in the FDA’s adverse event database, meaning the association had not been well established in product labeling despite real-world case reports.¹⁰ When a drug has been on the market for decades and its bladder effects are still being described as unexpected, that tells you something about how systematically we have been looking for them.

One interesting pattern across studies is that sertraline consistently shows up as having relatively lower rates of overactive bladder compared to other antidepressants. In the male study, sertraline users had an overactive bladder rate of about 28%, the lowest of any antidepressant examined.¹³ In the female study, sertraline again had the lowest rate among SSRIs examined.¹⁴ Whether that translates into a clinical recommendation to prefer sertraline when bladder side effects are a concern is the kind of judgment call that belongs with your prescriber, but it is a data point worth knowing about. The evidence on this topic is growing, and the picture is more nuanced than most drug information sheets suggest.

1
PubMed. Urinary side effects of psychotropic drugs: A systematic review and metanalysis
2
PubMed. Influence of central serotonergic mechanisms on lower urinary tract function
3
PubMed Central. Serotonin in the rat prefrontal cortex controls the micturition reflex through 5‐hydroxytryptamine 2A and 5‐hydroxytryptamine 7 receptors
4
The Journal of Pharmacology and Experimental Therapeutics. TAS-303, a Novel Selective Norepinephrine Reuptake Inhibitor that Increases Urethral Pressure in Rats, Indicating Its Potential as a Therapeutic Agent for Stress Urinary Incontinence
5
Life Sciences. Alterations in K+-evoked release of 3H-norepinephrine and contractile responses in urethral and bladder tissues induced by norepinephrine reuptake inhibition
6
Australian Prescriber. Anticholinergic drugs for overactive bladder
7
PubMed. Linking the evidence between urinary retention and antipsychotic or antidepressant drugs: A systematic review
8
PubMed Central. Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence
9
PubMed. Selective serotonin reuptake inhibitor-induced urinary incontinence
10
PubMed Central. Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
11
PubMed Central. Urinary retention caused by mirtazapine in a patient with geriatric depression: A case report
12
PubMed Central. Urinary Incontinence during Sleep Associated with Extended Release Form of Bupropion HCI
13
PubMed Central. Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study
14
PubMed. Assessment of overactive bladder in women antidepressant users
15
PubMed Central. The anticholinergic burden: from research to practice
16
Clinical Neuropharmacology. Escitalopram-Associated Acute Urinary Retention in Elderly Men With Known or Latent Benign Prostatic Hyperplasia
17
SpringerLink (Clinical Drug Investigation). Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
18
PubMed Central. Treatment of stress urinary incontinence with duloxetine hydrochloride
19
PubMed Central. Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System
20
PubMed. The Safety and Efficacy of Fluoxetine for the Treatment of Refractory Primary Monosymptomatic Nocturnal Enuresis in Children: A Randomized Placebo-Controlled Trial
21
PubMed. Drug-induced urinary retention: incidence, management and prevention